52 reports of this reaction
0.8% of all ROPIVACAINE HYDROCHLORIDE reports
#20 most reported adverse reaction
CONVULSION is the #20 most commonly reported adverse reaction for ROPIVACAINE HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 52 FDA adverse event reports linking ROPIVACAINE HYDROCHLORIDE to CONVULSION. This represents approximately 0.8% of all 6,839 adverse event reports for this drug.
Patients taking ROPIVACAINE HYDROCHLORIDE who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is a less commonly reported adverse event for ROPIVACAINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to convulsion, the following adverse reactions have been reported for ROPIVACAINE HYDROCHLORIDE:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 52 FDA reports for ROPIVACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 0.8% of all adverse event reports for ROPIVACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience convulsion while taking ROPIVACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.